Investor · 3 deals
Every published round VU Venture Partners took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| JumpStart Fertility | Unnamed stage | 2025 | $4m | Participant | Forbes Australia | |
| Nutromics | Unnamed stage | 9 Sep 2022 | $20.5m | Participant | Startup Daily (Wed 3 Sep 2025), SmartCompany, Startup Daily (Fri 9 Sep 2022), @AuManufacturing | |
| Mr Yum | Series A | 30 Nov 2021 | $89m | Participant | Ten13 portfolio, SmartCompany (Thu 21 Sep 2023), SmartCompany (Wed 31 May 2023), Startup Daily (Mon 24 Apr 2023), Startup Daily (Wed 22 Mar 2023), Forbes Australia, Beef Central / Grain Central, Startup Daily (Wed 24 Aug 2022), SmartCompany (Thu 23 Jun 2022), SmartCompany (Tue 3 May 2022), SmartCompany (Wed 8 Dec 2021), Women's Agenda, SmartCompany (Fri 3 Dec 2021), AgFunderNews, Startup Daily (Tue 30 Nov 2021), Australian FinTech, SmartCompany (Tue 30 Nov 2021), Tech Funding News - Australia, SmartCompany (Tue 30 Nov 2021), TechCrunch Australia, AirTree Ventures portfolio |
Companies VU Venture Partners has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| JumpStart Fertility | 2025 | 1 | 0 | |
| Mr Yum | 30 Nov 2021, Series A | 1 | 0 | |
| Nutromics | 9 Sep 2022 | 1 | 0 |
Fund closes reported for VU Venture Partners, as distinct from the investments it has made.
Companies VU Venture Partners has backed that another company then bought. An exit for the holding, not a deal VU Venture Partners did.
Stories naming VU Venture Partners. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne wearable diagnostics startup Nutromics raised US$14 million (A$20.5 million), led by Dexcom's venture arm with VU Venture Partners and Artesian, to fund clinical studies and expansion.